Long-term aspirin therapy as a predictor of decreased susceptibility to SARSCoV-2 infection in aspirin-exacerbated respiratory disease

Status

Completed

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-514602-31-00

Acronym

AERD-COV19

Enrollment

Registered

2024-07-01

Start date

2022-12-07

Completion date

2025-01-23

Last updated

2024-07-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aspirin-exacerbated respiratory disease

Brief summary

whether aspirin desensitization followed by long-term high-dose aspirin therapy in patients with AERD associated with lower gene expression of ACE2, TMPRSS2, BSG, PPIA, PPIB, DPP4, IFNA1, IFNB1 IFNG, IFNL1 i IFNL2 and ISG in sputum and nasal cells.

Detailed description

Whether the change of gene expression during aspirin therapy is connected with lower risk of SARS-CoV-2 infection

Interventions

DRUGACARD 300 mg

DRUG300 mg

DRUGtabletki

DRUGMicrocrystalline cellulose

DRUGNative corn starch

DRUGCitric acid anhydrous (E330)

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
whether aspirin desensitization followed by long-term high-dose aspirin therapy in patients with AERD associated with lower gene expression of ACE2, TMPRSS2, BSG, PPIA, PPIB, DPP4, IFNA1, IFNB1 IFNG, IFNL1 i IFNL2 and ISG in sputum and nasal cells.	—

Secondary

Measure	Time frame
Whether the change of gene expression during aspirin therapy is connected with lower risk of SARS-CoV-2 infection	—

Countries

Poland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026